 Neelanjan Mukherjee
Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA-Binding Proteins | 14 | 2025 | 451 | 2.150 |
Why?
| | RNA, Messenger | 16 | 2025 | 2812 | 1.580 |
Why?
| | RNA | 9 | 2025 | 916 | 1.570 |
Why?
| | Transcriptome | 7 | 2021 | 1059 | 0.990 |
Why?
| | Eukaryotic Initiation Factor-3 | 1 | 2025 | 10 | 0.930 |
Why?
| | Protein Biosynthesis | 5 | 2025 | 452 | 0.900 |
Why?
| | Polyadenylation | 3 | 2024 | 39 | 0.880 |
Why?
| | Small Molecule Libraries | 1 | 2025 | 113 | 0.840 |
Why?
| | Gene Expression Regulation | 8 | 2025 | 2625 | 0.770 |
Why?
| | Pteridines | 1 | 2023 | 22 | 0.770 |
Why?
| | Aldehydes | 1 | 2023 | 140 | 0.730 |
Why?
| | Aldosterone | 1 | 2021 | 42 | 0.690 |
Why?
| | Evolution, Molecular | 3 | 2024 | 502 | 0.680 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2021 | 147 | 0.650 |
Why?
| | RNA, Ribosomal | 1 | 2021 | 168 | 0.640 |
Why?
| | Ribonucleoproteins | 3 | 2019 | 90 | 0.630 |
Why?
| | ELAV-Like Protein 1 | 6 | 2021 | 17 | 0.560 |
Why?
| | Antigens, Surface | 3 | 2011 | 155 | 0.470 |
Why?
| | HEK293 Cells | 8 | 2019 | 745 | 0.460 |
Why?
| | RNA, Untranslated | 1 | 2016 | 123 | 0.440 |
Why?
| | Tristetraprolin | 1 | 2014 | 8 | 0.410 |
Why?
| | RNA Processing, Post-Transcriptional | 2 | 2011 | 90 | 0.390 |
Why?
| | Gene Expression Profiling | 5 | 2016 | 1794 | 0.380 |
Why?
| | Sequence Analysis, RNA | 6 | 2019 | 443 | 0.380 |
Why?
| | RNA Stability | 2 | 2025 | 108 | 0.370 |
Why?
| | Open Reading Frames | 3 | 2025 | 130 | 0.360 |
Why?
| | Ribosomes | 3 | 2025 | 193 | 0.360 |
Why?
| | Binding Sites | 6 | 2019 | 1319 | 0.310 |
Why?
| | RNA Precursors | 1 | 2011 | 154 | 0.310 |
Why?
| | MicroRNAs | 6 | 2019 | 695 | 0.270 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2025 | 10 | 0.230 |
Why?
| | 3' Untranslated Regions | 3 | 2025 | 149 | 0.230 |
Why?
| | Proteogenomics | 1 | 2025 | 12 | 0.230 |
Why?
| | Computational Biology | 4 | 2018 | 677 | 0.220 |
Why?
| | Neurites | 1 | 2025 | 51 | 0.220 |
Why?
| | Lymphocyte Activation | 1 | 2009 | 1140 | 0.220 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3565 | 0.220 |
Why?
| | Nonsense Mediated mRNA Decay | 1 | 2025 | 20 | 0.220 |
Why?
| | Codon, Nonsense | 1 | 2025 | 45 | 0.220 |
Why?
| | Estrous Cycle | 1 | 2025 | 22 | 0.220 |
Why?
| | Cell Hypoxia | 1 | 2025 | 249 | 0.210 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2025 | 121 | 0.210 |
Why?
| | Poly A | 1 | 2024 | 50 | 0.210 |
Why?
| | Giardia lamblia | 1 | 2024 | 23 | 0.210 |
Why?
| | Antigen Presentation | 1 | 2025 | 209 | 0.210 |
Why?
| | Ovary | 2 | 2025 | 236 | 0.210 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2024 | 27 | 0.210 |
Why?
| | Gene Regulatory Networks | 2 | 2025 | 318 | 0.210 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2024 | 54 | 0.210 |
Why?
| | Eukaryota | 1 | 2024 | 56 | 0.210 |
Why?
| | Immunoprecipitation | 3 | 2014 | 149 | 0.210 |
Why?
| | HLA Antigens | 1 | 2025 | 245 | 0.200 |
Why?
| | T-Lymphocytes | 2 | 2009 | 2017 | 0.200 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2025 | 300 | 0.200 |
Why?
| | Endosomes | 1 | 2024 | 140 | 0.200 |
Why?
| | Follicle Stimulating Hormone | 1 | 2025 | 266 | 0.190 |
Why?
| | ELAV Proteins | 3 | 2011 | 14 | 0.180 |
Why?
| | Humans | 28 | 2025 | 147306 | 0.180 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2025 | 456 | 0.170 |
Why?
| | Multiple Myeloma | 1 | 2025 | 310 | 0.170 |
Why?
| | Argonaute Proteins | 2 | 2019 | 32 | 0.170 |
Why?
| | Insulin-Secreting Cells | 1 | 2025 | 393 | 0.160 |
Why?
| | Angiotensin II | 1 | 2021 | 102 | 0.160 |
Why?
| | Phylogeny | 1 | 2024 | 924 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2025 | 889 | 0.160 |
Why?
| | Molecular Sequence Annotation | 2 | 2019 | 109 | 0.160 |
Why?
| | Interferons | 1 | 2021 | 186 | 0.150 |
Why?
| | Software | 3 | 2018 | 683 | 0.150 |
Why?
| | Herpesvirus 8, Human | 2 | 2011 | 67 | 0.150 |
Why?
| | Hydrocortisone | 1 | 2021 | 300 | 0.150 |
Why?
| | Base Sequence | 3 | 2019 | 2175 | 0.150 |
Why?
| | Peptides | 1 | 2025 | 1003 | 0.140 |
Why?
| | Breast Neoplasms | 2 | 2025 | 2420 | 0.140 |
Why?
| | Nucleotide Motifs | 1 | 2018 | 36 | 0.140 |
Why?
| | Gene Expression | 2 | 2016 | 1481 | 0.140 |
Why?
| | Drosophila melanogaster | 2 | 2019 | 241 | 0.140 |
Why?
| | Animals | 15 | 2025 | 38417 | 0.140 |
Why?
| | Proteome | 1 | 2023 | 520 | 0.140 |
Why?
| | RNA Splicing | 2 | 2017 | 285 | 0.140 |
Why?
| | RNA, Antisense | 2 | 2019 | 18 | 0.140 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 654 | 0.130 |
Why?
| | Drosophila Proteins | 1 | 2019 | 215 | 0.120 |
Why?
| | Signal Transduction | 4 | 2024 | 5272 | 0.120 |
Why?
| | RNA, Long Noncoding | 1 | 2019 | 173 | 0.120 |
Why?
| | DEAD-box RNA Helicases | 1 | 2017 | 84 | 0.120 |
Why?
| | Cells, Cultured | 2 | 2021 | 4170 | 0.110 |
Why?
| | RNA, Viral | 2 | 2011 | 695 | 0.110 |
Why?
| | Neoplasm Proteins | 2 | 2017 | 445 | 0.110 |
Why?
| | Phenotype | 1 | 2023 | 3216 | 0.110 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 643 | 0.110 |
Why?
| | DNA Damage | 1 | 2017 | 440 | 0.100 |
Why?
| | Mice | 10 | 2025 | 18493 | 0.100 |
Why?
| | RNA, Plant | 1 | 2013 | 10 | 0.100 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2014 | 145 | 0.100 |
Why?
| | Genome, Human | 1 | 2016 | 426 | 0.100 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2010 | 751 | 0.100 |
Why?
| | Regulatory Sequences, Ribonucleic Acid | 1 | 2012 | 18 | 0.090 |
Why?
| | Protein Interaction Mapping | 1 | 2013 | 105 | 0.090 |
Why?
| | Arabidopsis | 1 | 2013 | 96 | 0.090 |
Why?
| | Lymphoma, Primary Effusion | 1 | 2011 | 4 | 0.090 |
Why?
| | Transcription, Genetic | 2 | 2019 | 1456 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1457 | 0.080 |
Why?
| | Amino Acid Motifs | 1 | 2011 | 219 | 0.080 |
Why?
| | Nuclear Factor 90 Proteins | 1 | 2010 | 1 | 0.080 |
Why?
| | Poly(A)-Binding Proteins | 1 | 2009 | 4 | 0.080 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 599 | 0.080 |
Why?
| | Nanoparticles | 1 | 2016 | 524 | 0.070 |
Why?
| | Stilbenes | 1 | 2009 | 30 | 0.070 |
Why?
| | Jurkat Cells | 1 | 2009 | 115 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2016 | 2529 | 0.070 |
Why?
| | Thymus Gland | 1 | 2009 | 313 | 0.070 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2007 | 158 | 0.070 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2024 | 383 | 0.060 |
Why?
| | Kinetics | 1 | 2009 | 1569 | 0.060 |
Why?
| | RNA Transport | 1 | 2025 | 27 | 0.060 |
Why?
| | rho GTP-Binding Proteins | 1 | 2006 | 56 | 0.060 |
Why?
| | Peptide Chain Termination, Translational | 1 | 2025 | 9 | 0.060 |
Why?
| | Codon, Terminator | 1 | 2025 | 25 | 0.060 |
Why?
| | Radiation Tolerance | 1 | 2006 | 103 | 0.060 |
Why?
| | Algorithms | 1 | 2013 | 1868 | 0.050 |
Why?
| | Female | 6 | 2025 | 80081 | 0.050 |
Why?
| | Follicle Stimulating Hormone, beta Subunit | 1 | 2025 | 31 | 0.050 |
Why?
| | Cytoplasm | 1 | 2025 | 255 | 0.050 |
Why?
| | Adenoviridae | 1 | 2005 | 199 | 0.050 |
Why?
| | Biological Transport | 1 | 2025 | 425 | 0.050 |
Why?
| | Molecular Sequence Data | 3 | 2014 | 2886 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2005 | 178 | 0.050 |
Why?
| | Microtubule-Associated Proteins | 1 | 2005 | 197 | 0.050 |
Why?
| | Neoplasm Invasiveness | 1 | 2006 | 512 | 0.050 |
Why?
| | Paclitaxel | 1 | 2005 | 261 | 0.050 |
Why?
| | Protein Binding | 2 | 2024 | 2249 | 0.050 |
Why?
| | Cell Line | 3 | 2019 | 2832 | 0.050 |
Why?
| | Microtubules | 1 | 2025 | 267 | 0.050 |
Why?
| | Protein Transport | 1 | 2024 | 442 | 0.050 |
Why?
| | Multigene Family | 2 | 2014 | 210 | 0.050 |
Why?
| | RNA Interference | 2 | 2016 | 477 | 0.050 |
Why?
| | Glioblastoma | 1 | 2006 | 354 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 980 | 0.040 |
Why?
| | Substrate Specificity | 2 | 2012 | 387 | 0.040 |
Why?
| | Introns | 1 | 2019 | 260 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2005 | 986 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2025 | 3153 | 0.030 |
Why?
| | Radiation, Ionizing | 1 | 2017 | 86 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 2010 | 1049 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2006 | 1338 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2017 | 891 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2016 | 335 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 317 | 0.030 |
Why?
| | DNA Repair | 1 | 2017 | 256 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2014 | 387 | 0.020 |
Why?
| | Genome, Plant | 1 | 2013 | 36 | 0.020 |
Why?
| | Plant Roots | 1 | 2013 | 37 | 0.020 |
Why?
| | Systems Integration | 1 | 2013 | 36 | 0.020 |
Why?
| | Gene Expression Regulation, Plant | 1 | 2013 | 54 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2013 | 362 | 0.020 |
Why?
| | Epigenomics | 1 | 2013 | 125 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 86 | 0.020 |
Why?
| | Child Development Disorders, Pervasive | 1 | 2012 | 65 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2016 | 381 | 0.020 |
Why?
| | Cross-Linking Reagents | 1 | 2012 | 207 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2013 | 369 | 0.020 |
Why?
| | Signal-To-Noise Ratio | 1 | 2011 | 73 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2013 | 248 | 0.020 |
Why?
| | Macaca | 1 | 2010 | 66 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 2134 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2011 | 240 | 0.020 |
Why?
| | Operon | 1 | 2010 | 67 | 0.020 |
Why?
| | Eukaryotic Cells | 1 | 2010 | 35 | 0.020 |
Why?
| | Regulon | 1 | 2010 | 34 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 296 | 0.020 |
Why?
| | Receptors, Death Domain | 1 | 2009 | 4 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 365 | 0.020 |
Why?
| | Linear Models | 1 | 2011 | 852 | 0.020 |
Why?
| | Chromatin | 1 | 2013 | 561 | 0.020 |
Why?
| | Brain | 2 | 2012 | 3009 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2010 | 398 | 0.020 |
Why?
| | Chemokines | 1 | 2009 | 217 | 0.020 |
Why?
| | Fanconi Anemia Complementation Group Proteins | 1 | 2007 | 7 | 0.020 |
Why?
| | Cell Transformation, Viral | 1 | 2007 | 23 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2011 | 539 | 0.020 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2007 | 43 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4354 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2008 | 244 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2007 | 196 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 547 | 0.020 |
Why?
| | HeLa Cells | 1 | 2008 | 633 | 0.010 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 64 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 2006 | 269 | 0.010 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2005 | 46 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3448 | 0.010 |
Why?
| | Cell Cycle Proteins | 1 | 2009 | 633 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 6042 | 0.010 |
Why?
| | Stem Cells | 1 | 2009 | 630 | 0.010 |
Why?
| | Caspases | 1 | 2005 | 233 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2006 | 762 | 0.010 |
Why?
| | Mice, Nude | 1 | 2005 | 680 | 0.010 |
Why?
| | Transfection | 1 | 2006 | 930 | 0.010 |
Why?
| | Saccharomyces cerevisiae | 1 | 2008 | 585 | 0.010 |
Why?
| | Blotting, Western | 1 | 2006 | 1186 | 0.010 |
Why?
| | Genetic Therapy | 1 | 2005 | 317 | 0.010 |
Why?
| | ErbB Receptors | 1 | 2006 | 638 | 0.010 |
Why?
| | Up-Regulation | 1 | 2005 | 848 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2007 | 878 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 4130 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2009 | 2054 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2008 | 1368 | 0.010 |
Why?
| | Models, Biological | 1 | 2008 | 1772 | 0.010 |
Why?
| | Male | 3 | 2014 | 73954 | 0.010 |
Why?
| | Rats | 1 | 2006 | 5613 | 0.010 |
Why?
| | Apoptosis | 1 | 2005 | 2454 | 0.010 |
Why?
| | Child | 1 | 2012 | 22980 | 0.010 |
Why?
| | Adult | 1 | 2014 | 41406 | 0.000 |
Why?
|
|
Mukherjee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|